Zhejiang Dayang Biology Technology Co.,Ltd.

Shenzhen Stock Exchange 003017.SZ

Zhejiang Dayang Biology Technology Co.,Ltd. Gross Profit for the year ending December 31, 2023: USD 23.42 M

Zhejiang Dayang Biology Technology Co.,Ltd. Gross Profit is USD 23.42 M for the year ending December 31, 2023, a 10.50% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Zhejiang Dayang Biology Technology Co.,Ltd. Gross Profit for the year ending December 31, 2022 was USD 21.19 M, a -11.50% change year over year.
Zhejiang Dayang Biology Technology Co.,Ltd. Gross Profit for the year ending December 31, 2021 was USD 23.95 M, a -5.66% change year over year.
Zhejiang Dayang Biology Technology Co.,Ltd. Gross Profit for the year ending December 31, 2020 was USD 25.38 M, a 13.12% change year over year.
Zhejiang Dayang Biology Technology Co.,Ltd. Gross Profit for the year ending December 31, 2019 was USD 22.44 M, a 2.61% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Shenzhen Stock Exchange: 003017.SZ

Zhejiang Dayang Biology Technology Co.,Ltd.

CEO	Mr. Yanggui Chen
IPO Date	Oct. 26, 2020
Location	China
Headquarters	No. 22 Chaoyang Road
Employees	839
Sector	Materials
Industries Fertilizers Chemicals & Advanced Materials Cleaning Supplies Organic Foods Personal Care Pet Food Petrochemicals Plastics

Description

Zhejiang Dayang Biology Technology Co.,Ltd. engages in research and development, production, and sale of biological products, agricultural chemicals, and chemical in China and internationally. The company's products include food additive potassium carbonate, potassium carbonate, food additive potassium bicarbonate, potassium bicarbonate, agricultural grade ammonium chloride, and industrial grade ammonium chloride. It also offers chemical products, such as 2-chloro-6-fiuorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride, and anisole products; veterinary APIs, including amprolium HCL; and veterinary drug premixes comprising enramycin premixes. The company was founded in 1976 and is based in Jiande, China.

Key trends

Past 5 years